What iDEL Therapeutics does

iDEL's current pipeline consists of two lead programs being advanced toward clinical evaluation: Lead Candidate #1, a single-domain antibody for intracellular oncogene targeting, and Lead Candidate #2, a Multicancer Drug Conjugate (MDC). The company is pre-revenue, with no commercial products, and its disclosed revenue model anticipates value creation through strategic partnerships and future licensing/royalties once candidates progress clinically. It publicly launched in March 2026 with a €9 million seed financing led by BiomedVC (with NRW.Venture, Gründerfonds Ruhr, and KHAN Technology Transfer Fund II) and is led by an experienced founding team and board, including a Chair with a prior €1 billion-plus pharma exit (Cardior/Novo Nordisk). The company is positioning itself for outbound business development, including a scheduled presentation at Bio€quity Europe in May 2026.

Name

iDEL Therapeutics

Legal name

iDEL Therapeutics GmbH

Website

https://idel-tx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

iDEL Therapeutics is a Dortmund-based, pre-clinical biotech developing a synthetic shuttle platform that delivers therapeutics directly into the cytosol of solid tumor cells to bypass endosomal trapping and access intracellular cancer targets.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

akta.pro secondary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Cancer therapeutics
• Drug delivery platform
• Intracellular targeting
• Oncology pipeline
• Synthetic shuttle technology

Headquarters

HQ city

Dortmund

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pipeline Development and Clinical Advancement: As a pre-revenue biotech company founded in 2025, iDEL Therapeutics is focused on advancing its oncology pipeline toward clinical evaluation. The company plans to create scalable value through strategic partnerships. Revenue generation will depend on successful clinical development, regulatory approval, and commercialization of its cancer therapeutics.

Go-to-market motion1 record

Marketing channels5 records

Core offering

iDEL Therapeutics develops a proprietary synthetic shuttle platform that delivers therapeutic payloads directly into the cytosol of tumor cells, bypassing endosomal entrapment and unlocking previously undruggable intracellular cancer targets. The company is advancing two preclinical lead candidates — a single-domain antibody for intracellular oncogene targeting (Lead Candidate #1) and a Multicancer Drug Conjugate (MDC, Lead Candidate #2) — and intends to create value through clinical advancement and strategic partnerships.

Product overview

iDEL Therapeutics is developing a pipeline of cancer therapeutics based on its proprietary synthetic shuttle platform for direct cytosolic drug delivery. The platform consists of two lead programs: Lead Candidate #1 (a single-domain antibody targeting intracellular oncogenes) and Lead Candidate #2 (a multicancer drug conjugate). The technology enables delivery of both large and small molecules directly into tumor cell cytosol, bypassing endosomal trapping that limits conventional therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• iDEL Synthetic Shuttle Platform A modular, synthetic shuttle system that transports therapeutic payloads directly into the cytosol of tumor cells, bypassing endosomal trapping and enabling access to previously undruggable intracellular targets for treating solid tumors. Designed as a plug-and-play platform for out-licensing and strategic partnerships.
• Lead Candidate #1 (Single-domain antibody for intracellular oncogen targeting) A single-domain antibody therapeutic designed for direct cytosolic delivery via the iDEL shuttle platform to target intracellular oncogenes in solid tumors; currently in preclinical development.
• Lead Candidate #2 (MDC - Multicancer Drug Conjugate) A multicancer drug conjugate (MDC) built on the synthetic shuttle platform, designed for targeted cancer therapy across multiple tumor types; currently in preclinical development.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Strategic Partnership CandidatesexploratoryStrategic or Co-development PartnerCompany is actively seeking strategic partnerships to jointly expand therapeutic possibilities and increase patient benefit across cancer indications. The versatile plug-and-play platform enables delivery of a wide spectrum of payloads from small molecules to large molecules.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Molecular Partners: Molecular Partners develops DARPin-based therapeutics, an engineered protein scaffold platform for oncology and ophthalmology. Its modular, engineered-protein approach to targeted therapeutics is highly comparable to iDEL's synthetic shuttle protein engineering strategy.
• Heidelberg Pharma: Heidelberg Pharma develops antibody-targeted Amanitin conjugates (ATACs) and ADC platforms with proprietary linker chemistry. Comparable to iDEL because it is also a platform-based targeted cancer payload delivery company addressing solid tumors with novel chemistry.
• Tubulis: Tubulis builds next-generation ADCs with proprietary payload and linker chemistries to improve therapeutic index in solid tumors. Comparable as a European biotech developing modular targeted delivery platforms for cancer therapeutics, similar stage and funding profile.
• Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptides (Bicycles) engineered to penetrate cells and bind intracellular protein targets, addressing the same undruggable intracellular space as iDEL's shuttle platform. It is the most analogous peer in cytosolic delivery of therapeutic payloads to solid tumors.

Emerging players

• Abalos Therapeutics: Abalos Therapeutics develops engineered viruses to induce anti-tumor immune responses in solid tumors. Directly relevant because iDEL's CEO Dr. Marcus Kostka was previously CEO of Abalos (2019-2024), making it a comparable European preclinical/early-clinical oncology platform.
• Tessellate Bio: Tessellate Bio (now Elasmogen) develops next-generation cancer therapies, and is directly relevant because iDEL's CSO Dr. Jürgen Moll was previously CSO at Tessellate Bio and led a €500M+ deal with Boehringer Ingelheim. Comparable novel oncology modality focus.
• MODAG GmbH: MODAG develops targeted therapies for neurodegenerative diseases and was co-founded by iDEL's CEO Marcus Kostka. Comparable as a small European biotech emerging from academic research with a novel small-molecule mechanism in an area of high unmet need.
• Araris Biotech: Araris Biotech develops site-specific ADCs using its proprietary linker technology for oncology. Comparable as a European ADC platform peer aiming to improve intracellular payload delivery to tumor cells, though focused on ADC format rather than broad shuttle delivery.
• BioAtla: BioAtla develops Conditionally Active Biologics (CABs) that target tumor-specific microenvironments with engineered antibodies and ADCs. Comparable in its protein-engineering approach to selectively engage solid tumors and deliver cytotoxic payloads intracellularly.
• Cardior Pharmaceuticals: Cardior Pharmaceuticals developed RNA-based therapeutics for heart disease and was acquired by Novo Nordisk for over €1B. Relevant as iDEL's Board Chair Dr. Claudia Ulbrich led Cardior to that exit, providing a comparable European biotech exit narrative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/idel-therapeutics-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iDEL Therapeutics